[New] Escalating pharmaceutical trade tensions may create opportunities for Brazil's generic medicines sector as global manufacturers reassess export strategies.
Fitch Solutions
[New] Brazil's government consideration of pharmaceutical patents as a retaliatory tool against US tariffs will elevate intellectual property risks for innovative multinational drugmakers.
Fitch Solutions
[New] Moderate Growth Amid Strategic Restructuring And Pricing Pressures In 2026, pharmaceutical sales across most markets will exhibit moderate growth, driven by sustained demand and new product launches across most regions, though ongoing government cost containment pressures will constrain expansion.
Fitch Solutions
[New] Fastest-growing Region: Asia Pacific projected to expand at a CAGR of 5.6%, supported by government-led sustainability policies and growth in food and pharmaceutical packaging sectors.
Persistence Market Research
[New] As one of the Seven Key Global Biopharmaceutical Trends and Emerging Opportunities in 2026, AI is creating sustained growth opportunities across pharmaceutical ingredients, technology transfer, product licensing, regional distribution, and global commercialization partnerships.
demo4.wpbeginner.site
[New] Pharmaceuticals represent the fastest-growing end use segment, expanding at a CAGR of 8.2% between 2026 and 2033, driven by rising regulatory compliance requirements and growing automation investment across pharmaceutical manufacturing facilities worldwide.
Persistence Market Research
[New] Germany is anticipated to advance at 24.4% CAGR, owing to pharmaceutical export depth.
FactMr
[New] By Bioreactor Mode: Fed-batch is anticipated to capture 37.0% share in 2026 due to its broad use in monoclonal antibody and biosimilar production.
FactMr
[New] The Food and Drug Administration recently approved an updated COVID vaccine for people 65 and over, as well as for younger people who have a condition that increases their risk of severe illness from COVID.
NewYork-Presbyterian
[New] Researchers from the National University of Singapore's Yong Loo Lin School of Medicine (NUS Medicine) have discovered a drug that turns off a master switch driving tumour growth in triple-negative breast cancer, which could lead to better, more personalised treatments for the aggressive cancer.
ST
[New] Recent announcements of 100% (later 200%) tariffs on generics from 2028 onwards pose a significant risk to foreign suppliers and to patients.
Coface
[New] Fastest Growing Region - Asia Pacific is set to register the highest CAGR through 2033, fueled by universal health coverage expansion, China's drug access reforms, India's generic drug manufacturing leadership, and rapid e-pharmacy growth across Southeast Asia.
Persistence Market Research
[New] The pharmaceutical sector is projected to grow at a CAGR of 8.2% from 2026 to 2032, driven by rising demand for bioactive compounds derived from pork in nutraceuticals and specialty health products.
6wresearch
[New] The medical polymers industry was worth USD 20 billion in 2022 and is projected to grow at 8.3% each year until 2032, due to the rising demand for pharmaceutical devices.
Global Market Insights Inc.
[New] Insilico leads a pack of companies using AI to rapidly come up with drug ideas humans might never think of, potentially speeding the race to new cures.
MIT Technology Review
[New] The drug discovery & development segment is anticipated to register the fastest CAGR of 8.43% during 2026-2034.
Straits Research
[New] As personalized medicine and biosimilar manufacturing scale globally, the demand for AI-enabled continuous bioprocessing platforms will intensify, positioning digital biomanufacturing solution providers at the center of a major manufacturing paradigm shift.
Persistence Market Research
[New] The Small Volume Bags segment is projected to register the fastest growth at a CAGR of 6.8% from 2026 to 2033, driven by increasing demand for precise drug delivery and specialty treatments.
Data Bridge Market Research
[New] By 2026, complex drug candidates are routinely evaluated computationally to forecast toxicity and binding before lab work even begins.
BuildEZ
[New] Key Opportunity - Generics represent a compelling margin opportunity, accounting for over 90% of U.S. prescriptions and saving US$ 408 billion annually per AAM data, with India's 10,000+ Jan Aushadhi Kendras and EU biosimilar policy driving further volume growth.
Persistence Market Research
[New] The first IRA negotiated prices took effect in 2026, and the interaction patterns with biosimilar timing will become clearer as more biologics enter the negotiation process while facing biosimilar competition simultaneously.
DrugPatentWatch - Transform Data into Market Domination
Last updated: 01 September 2026
Hi,
Would you like a quick online demo of our service from an experienced member of our team?
